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Highlights 17 
 Mannheimia haemolytica and Pasteurella multocida isolates were obtained from 18 
cattle with respiratory disease. 19 
 The pharmacodynamics of oxytetracycline were determined for M. haemolytica 20 
and P. multocida. 21 
 Minimum inhibitory concentrations were substantially higher in serum than in 22 
broth. 23 
 Serum broth differences were not attributable to protein binding. 24 
 The clinical efficacy of oxytetracycline may not depend solely on killing bacteria. 25 
Abstract 26 
The in vitro pharmacodynamics of oxytetracycline were established for six isolates of 27 
each of the calf pneumonia pathogens Mannheimia haemolytica and Pasteurella multocida. 28 
Minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC) and 29 
bacterial time-kill curves were determined in two matrices, Mueller Hinton broth (MHB) and 30 
calf serum. Geometric mean MIC ratios, serum:MHB, were 25.2:1 (M. haemolytica) and 31 
27.4:1 (P. multocida). The degree of binding of oxytetracycline to serum protein was 52.4%. 32 
Differences between serum and broth MICs could not be accounted for by oxytetracycline 33 
binding to serum protein. In vitro time-kill data suggested a co-dependent killing action of 34 
oxytetracycline. The in vitro data indicate inhibition of the killing action of oxytetracycline by 35 
serum factor(s). The nature of the inhibition requires further study. The outcome of treatment 36 
with oxytetracycline of respiratory tract infections in calves caused by M. haemolytica and P. 37 
multocida may not be related solely to a direct killing action. 38 
 39 
Keywords: Mannheimia haemolytica; Pasteurella multocida; Bovine; Oxytetracycline; 40 
Pharmacodynamics  41 
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 3 
Introduction 42 
Oxytetracycline is an antimicrobial drug with a broad spectrum of activity. The 43 
spectrum includes two bacterial pathogens implicated in bovine pneumonia, Mannheimia 44 
haemolytica and Pasteurella multocida (Nouws and Vree, 1983; Nouws et al., 1985; Nouws 45 
et al., 1990; Esaki et al., 2005). Oxytetracycline is still used extensively, despite the 46 
development of resistance in some species of bacteria. It is available in long acting, high 47 
strength formulations. These depot formulations provide sustained absorption from the site of 48 
injection (Nouws and Vree, 1983; Toutain and Raynaud, 1983; Davey et al., 1985; Nouws et 49 
al., 1990). 50 
 51 
The potency of antimicrobial drugs is generally determined in vitro, based on the 52 
minimum inhibitory concentration (MIC). The widely accepted standards for MIC 53 
determination have been defined by the European Union Committee on Antimicrobial 54 
Sensitivity testing (EUCAST) and the Clinical Laboratory Standards Institute (CLSI); they 55 
ensure reproducible findings and thereby enable data to be harmonised internationally. This is 56 
essential when comparing data from several laboratories, between countries and across time 57 
periods for susceptibility testing. The two-fold dilution used is important because, when 58 
plotted on a histogram, the distributions are log-normal when using a log2 distribution. The 59 
plots of histograms are more easily examined for the purpose of identifying wild-type 60 
distributions. 61 
 62 
However, the standardised CLSI/EUCAST methods of determining MIC have two 63 
drawbacks for the purposes of this study. Firstly, they are based on two-fold, dilutions, with 64 
the potential consequence of up to 100% error, thus having a limitation regarding accuracy on 65 
single isolate estimates. Accuracy rather than precision is of importance in generating MIC 66 
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data for the purpose of using pharmacodynamic (PD) data together with pharmacokinetic 67 
(PK) data for the purpose of dose prediction. To meet (in part) this concern, previous studies 68 
have used five sets of overlapping doubling dilutions to reduce inaccuracy on single isolate 69 
estimates (Aliabadi and Lees, 2001; Sidhu et al., 2010). Secondly, CLSI/EUCAST standards 70 
for MIC determinations are based on the use of artificial growth media. Whilst these provide 71 
optimal growth conditions in vitro, they differ in composition from biological fluids. 72 
 73 
To provide comparisons between broths and biological fluids, previous studies have 74 
been undertaken in calf serum and inflammatory exudates (Aliabadi and Lees, 2001, 2002; 75 
Sidhu et al., 2003; Sidhu et al., 2010). A M. haemolytica isolate of calf origin had a MIC in 76 
serum 19 times greater than the broth MIC (Brentnall et al., 2012). Hence, the quantitative 77 
determination of PD indices with improved accuracy and in biological matrices, for some 78 
drug classes, may be helpful to the application of PK/PD approaches to dose determination. It 79 
is accepted that the vast majority of the published literature has relied on either EUCAST or 80 
CLSI methodology for determining MIC. This article therefore extends those findings. 81 
 82 
Some authors recommend restriction of the term MIC for measurements undertaken in 83 
broths recommended by CLSI and EUCAST, with the requisite fluid being defined for each 84 
pathogenic species. However, the term MIC has been accepted in the peer reviewed literature, 85 
for other growth matrices and is retained in this article (Honeyman et al., 2015). 86 
 87 
The aim of this study was to evaluate factors influencing the antimicrobial PDs of 88 
oxytetracycline for two calf pneumonia pathogens, M. haemolytica and P. multocida. The 89 
objectives were: (1) to compare in vitro MIC, MBC and time-kill profiles of oxytetracycline 90 
in two matrices, Mueller Hinton Broth (MHB) and calf serum; (2) to investigate the influence 91 
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of serum on MHB MICs by combining the two matrices in varying proportions; (3) to 92 
determine the effect of low, intermediate and high bacterial counts on oxytetracycline MICs; 93 
(4) to compare in vitro time-kill curves for oxytetracycline in MHB and calf serum; and (5) to 94 
determine the degree of binding of oxytetracycline to protein in calf serum. 95 
 96 
Materials and methods 97 
Origin, storage, selection and culture of bacterial isolates 98 
Twenty isolates of each of two calf pathogens, M. haemolytica and P. multocida, were 99 
obtained post-mortem from field cases of calf pneumonia in various geographical regions of 100 
the United Kingdom. They were supplied on swabs by the Veterinary Laboratories Agency 101 
(AHVLA), now Animal and Plant Health Agency (APHA), and stored at -70 °C in 102 
glycerol:milk:water (20:10:70). This fluid was boiled for 5 s, left to cool for 12 h and then 103 
boiled again for a further 5 s. 104 
 105 
Two criteria were used to select 6/20 isolates of each of the two bacterial species for 106 
further study: (1) each isolate was investigated for its ability to grow logarithmically in four 107 
fluids (MHB and calf serum, exudate and transudate); (2) each isolate was evaluated for 108 
susceptibility to oxytetracycline by disc diffusion and measurement of diameter of zone of 109 
growth inhibition. Since tetracycline but not oxytetracycline is listed in the CLSI standards, 110 
this measurement was not determined according to CLSI (2008). MICs were then determined 111 
in MHB, using doubling dilutions. 112 
 113 
Culture methods and bacterial viability counts, determined by serial dilution and spot-114 
plate counts, were as described by Lees et al. (2015). 115 
 116 
Page 5 of 21
 6 
Minimum inhibitory and minimum bactericidal concentrations 117 
MICs for six isolates each of M. haemolytica and P. multocida were determined by 118 
broth microdilution in accordance with CLSI methods (CLSI, 2008), except that: (1) our study 119 
used MHB whereas CLSI requires use of cation adjusted MHB and, in future studies, the 120 
former would be preferred; and (2) to improve accuracy, five overlapping sets of 121 
doubling/two-fold dilutions of oxytetracycline were prepared in MHB, instead of the CLSI 122 
standard, which uses one set of doubling dilutions. Quality control (QC) organisms were not 123 
tested in this study to validate the assay because, for a small number of isolates, six of each of 124 
two species (as opposed to testing hundreds/thousands of isolates in constructing MIC 125 
distributions), this works well. What mattered more for this study was to reduce the error on 126 
individual estimates for a small number of isolates (12) from up to 100% to no more than 127 
20%. This we did on the advice of A. Rycroft, Royal Veterinary College, University of 128 
London, United Kingdom). 129 
 130 
The methods for MIC and MBC determinations were as previously described (Lees et 131 
al., 2015). The bactericidal assay was performed according to methods that have not been 132 
standardised by CLSI or EUCAST. QC was not performed on the MIC tests conducted for 133 
this study on oxytetracycline, because CLSI and EUCAST methods are based on tetracycline 134 
and not oxytetracycline. MIC determinations for the six isolates of both bacterial species were 135 
repeated, using five sets of overlapping two-fold dilutions of oxytetracycline prepared in 136 
bovine serum (Gibco). The influence of serum/MHB mixtures and inoculum size on MIC was 137 
determined as described in Appendix A. 138 
 139 
Antimicrobial growth (time-kill) curves 140 
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 For six isolates each of M. haemolytica and P. multocida, in vitro time-kill curves 141 
were established using oxytetracycline concentrations corresponding to 0.25, 0.5, 1, 2 and 4x 142 
multiples of MIC in both MHB and calf serum, as previously described (Lees et al., 2015). 143 
The lowest quantifiable count was 33 colony forming units (CFU)/mL. Ex vivo analyses were 144 
performed as described in Appendix B. 145 
 146 
Serum protein binding of oxytetracycline 147 
The degree of binding of oxytetracycline to serum protein in vivo was determined in 148 
triplicate on pooled samples from 10 calves harvested from a tissue cage study for seven 149 
concentrations, ranging from 0.43 to 2.07 µg/mL. The total concentration was measured on 150 
each sample as described in Appendix B and binding to protein was determined on a second 151 
aliquot of each sample by ultracentrifugation at 4,000 g and 25 °C for 20 min. The 152 
ultrafiltration device used was an Amicon Ultra Centrifugal filter (Ultracel 10 K, Millipore) 153 
and oxytetracycline concentrations were re-determined on the ultrafiltrate. 154 
 155 
Statistical analyses 156 
MIC and MBC data are presented as geometric means and standard deviation (SD). 157 
Differences in MIC and MBC values between MHB and serum were compared with a paired t 158 
test or the non-parametric Wilcoxon test, depending on whether the data passed a normality 159 
test. 160 
 161 
Results 162 
Selection of isolates 163 
Six isolates of each species were selected to satisfy two criteria. Firstly, the 164 
percentages growing logarithmically were 65, 65, 40 and 55 for M. haemolytica and 90, 75, 165 
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65 and 65 for P. multocida for MHB, calf serum, exudate and transudate, respectively. 166 
Secondly, initial MIC studies using doubling dilutions indicated that the MIC for MHB was ≤ 167 
0.4 µg/mL. It should be noted CLSI tables do not provide a separate breakpoint for 168 
oxytetracycline, but CLSI provides a breakpoint for tetracycline (≤ 2 µg/mL), and indicates 169 
that the breakpoint interpretation for tetracycline also applies to oxytetracycline. Therefore, 170 
the oxytetracycline MICs were less than the tetracycline breakpoint. The six isolates of each 171 
species selected comprised highest, lowest and four with intermediate MICs. 172 
 173 
Minimum inhibitory and minimum bactericidal concentrations 174 
MICs of the 12 selected isolates were re-determined separately in MHB and serum. 175 
MICs and MBCs are illustrated in Fig. 1. Table 1 presents geometric mean MICs and MBCs, 176 
and ratios MBC:MIC. The potency of oxytetracycline, expressed as MIC, was 25.2 times 177 
greater in MHB for M. haemolytica and 27.4 times greater in MHB for P. multocida, 178 
compared to serum MICs. Therefore, potency differed markedly between the two growth 179 
matrices. Using MBC as the indicator of potency indicated smaller differences than for MIC, 180 
but again in favour of MHB. 181 
 182 
Time-kill curves 183 
Starting inoculum counts of the order of 10
7 
CFU/mL were selected to reflect a 184 
moderate to high bacterial load in clinical subjects (Roof, 2011). Despite marked differences 185 
in MICs between MHB and serum, growth inhibition curves in these matrices using multiples 186 
of MIC were broadly similar for M. haemolytica (Fig. 2). However, reductions in count were 187 
smaller in serum than in MHB at MIC multiples of 2.0 and 4.0. With both matrices, some re-188 
growth occurred at 24 h. The in vitro killing pattern was classified as co-dependent (on both 189 
concentration and time). For P. multocida in MHB, MIC multiples of 2.0 and 4.0 produced 190 
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virtual eradication by 24 h (Fig. 3). In serum, the killing action at 24 h was less marked at 2x 191 
and 4x MIC than in MHB, with some re-growth occurring. The in vitro killing action was 192 
judged to be co-dependent for both matrices (Fig. 3). Ex vivo time-kill curves are shown in 193 
Appendix B. 194 
 195 
Binding to serum protein 196 
Oxytetracycline binding to protein was established for a range of seven in vivo 197 
concentrations (0.43 to 2.07 µg/mL) in pooled serum samples. Mean percentage protein 198 
binding ± SD was 52.4 ± 7.3 and was independent of total concentration. 199 
 200 
Discussion 201 
Many previous studies have shown that, for some drugs of the macrolide/triamilide 202 
groups, MICs determined in serum are much higher than those determined using the broths 203 
recommended in CLSI and EUCAST guidelines. An example is tulathromycin; for this drug 204 
Toutain et al. (2016) reported MICs some 50 times lower in bovine serum than in broths for 205 
M. haemolytica and P. multocida of bovine origin. When serum values were corrected for 206 
drug binding to serum protein, differences were even greater; causes have not been positively 207 
determined. In contrast, in this study the ‘serum effect’ was reversed; MICs were higher in 208 
broth than in serum. Toutain et al. (2016) showed clearly that accuracy of MIC determination, 209 
to be used in dose prediction, can be obtained from the approved broth MIC data by applying 210 
a robust scaling factor to bridge in vitro MHB to in vivo relevant serum/plasma/blood values. 211 
Oxytetracycline MICs were reported against a single bovine isolate of M. haemolytica (A1 212 
76/1), in five matrices (Brentnall et al., 2012, 2013); values (µg/mL) were 0.5 (MHB), 0.8 213 
(cation adjusted MHB), 14.8 (serum), 12.8 (exudate) and 11.2 (transudate). Therefore, MIC 214 
differed markedly between three biological fluids on the one hand and two artificial media on 215 
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the other, whilst similar values were obtained for the two artificial matrices and similar values 216 
were obtained for the three biological fluids. 217 
 218 
These findings were confirmed and extended to demonstrate: (1) much higher MICs of 219 
oxytetracycline in serum compared to MHB for M. haemolytica and P. multocida; (2) higher 220 
oxytetracycline MBCs in serum compared to MHB, but with lower serum:MHB ratios for 221 
MBC than for MIC. This study also quantified inter- and intra-species differences in 222 
variability for six isolates of each species; coefficient of variation (CV%) serum values for M. 223 
haemolytica were 84 (MIC) and 62 (MBC). Corresponding CV%s for P. multocida were 224 
lower (38 MIC; 33 MBC). Considering the serum MIC values reported in this study, and 225 
species and isolate variability, it is important for future studies to recognise that we used 226 
bovine serum from a single source. Breed, age, sex, disease state, country and other factors 227 
might provide MIC differences between sera, even from a single species. Such differences 228 
should be quantified. However, this paper had a more limited immediate goal, to compare 229 
broth with serum from the target species derived from one source only. 230 
 231 
The cause(s) of serum/MHB differences in MIC for oxytetracycline have not been 232 
established. In a recent study, albumin concentrations in MHB and calf serum were 0.033 and 233 
32.2 g/L, thus differing by approximately 1,000-fold (Brentnall et al., 2012). Most serum 234 
protein binding occurs to albumin and it is very likely that total and free concentrations of 235 
oxytetracycline in MHB were identical. Therefore, approximately two-fold higher MIC values 236 
in serum compared to MHB would be anticipated from the binding of oxytetracycline to 237 
serum protein, which was shown to be 52.4% of total concentration. This confirms the 50% 238 
binding described by Pilloud (1973) and is intermediate between 18.6% (Ziv and Sulman, 239 
1972) and 72% (Nouws et al., 1985) described for cattle by other authors. Cause(s) of 240 
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differing degrees of protein binding in these studies are not known, but it should be noted that 241 
the degree of binding has an impact on dosages required to achieve a given level of efficacy. 242 
The prediction of approximately two-fold higher MICs in serum in the present study arises 243 
because protein bound AMDs are microbiologically inactive (Wise, 1986; Zeitlinger et al., 244 
2004). This relatively small (two-fold) predicted difference is well short of the 25- to 27-fold 245 
experimentally determined differences in MIC between MHB and serum for M. haemolytica 246 
and P. multocida, respectively. 247 
 248 
In quantitative terms, for P. multocida, correction for protein binding yields a mean 249 
fraction unbound (fu) serum MIC of 3.21 µg/mL, whilst broth MIC was 0.25 µg/mL; thus, the 250 
mean fu serum MIC is 12.9-fold greater than the broth MIC, which is the CLSI and EUCAST 251 
and therefore universally accepted standard. For M. haemolytica, the fu serum MIC was 11.8 252 
times greater than broth MIC. The data indicate inhibition of the killing action of 253 
oxytetracycline by some serum factor(s). The data demonstrate antagonism of the action of 254 
oxytetracycline beyond what can be ascribed to non-specific protein binding. 255 
 256 
The nature of the inhibition requires further consideration. In addition to albumin 257 
content, other differences in composition between MHB and calf serum include higher 258 
globulin, sodium, chloride, potassium, calcium and magnesium concentrations (Brentnall et 259 
al., 2012). Since oxytetracycline can bind covalently to calcium and magnesium ions, this 260 
might theoretically explain the serum/broth MIC and MBC differences. However, Luthman 261 
and Jacobsson (1983) reported that oxytetracycline did not chelate with calcium ions in calf 262 
serum. Moreover, the MIC difference between MHB and cation adjusted MHB reported by 263 
Brentnall et al. (2012) was slight (0.5 and 0.8 µg/mL, respectively). Therefore, the cause(s) of 264 
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the marked differences in MIC between MHB and cation adjusted MHB on the one hand and 265 
calf serum on the other require alternative explanations and further study. 266 
 267 
Honeyman et al. (2015) compared MICs of several tetracyclines in broth and 50% 268 
broth:50% mouse serum as matrices. For a strain of Streptococcus pneumoniae, MICs were 269 
identical for six compounds but, with added serum, 2-4 fold increases were obtained for five, 270 
whilst MIC was increased 32-fold for one compound. In contrast, for a strain of 271 
Staphylococcus aureus, MIC was increased in the broth:serum combined matrix relative to 272 
broth for all 12 compounds investigated and, for seven, the increase was in the range 8- to 273 
128-fold. 274 
 275 
The PDs of oxytetracycline was further investigated in time-kill studies. Using 276 
multiples of up to 4x MIC indicated a probable co-dependent killing mechanism that is 277 
dependency on both concentration and time. However, confirming the type of killing action 278 
would benefit from further studies using higher multiples of MIC than the five used in this 279 
study. 280 
 281 
These data suggest that serum, exudate and transudate may be useful alternatives to 282 
broth for potency determination, when the objective is estimation of a dose for clinical use, 283 
based on PK/PD modelling approaches. These biological fluids are not identical to pulmonary 284 
epithelial lining fluid, but are much closer in composition to the latter than artificial broths. 285 
Further refinement of the methodology used in this study would be to determine potency in 286 
serum in the presence of other ‘natural’ constituents, such as leucocytes and antibodies, as 287 
well as the normal bacterial flora that compete with pathogens. Ideally, although technically 288 
difficult, it would also be relevant to determine potency in pulmonary epithelial ling fluid. 289 
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 290 
Despite these considerations, in immunocompetent animals with pneumonic 291 
infections, even the limited direct killing activity in serum demonstrated in this study might 292 
contribute to efficacy, particularly in those cases with mild infection, treated early, in which 293 
biophase bacterial counts would normally be low. Epidemiological data on oxytetracycline 294 
MICs have indicated a bimodal distribution (Yoshimura et al., 2001). Even allowing for these 295 
MICs, measured conventionally in an artificial growth matrix, some 40-50% of isolates had 296 
MICs of 8.0 or 16.0 µg/mL for calf strains of M. haemolytica and P. multocida. On the other 297 
hand, 30 to 40% of isolates had broth MICs of 0.50 µg/mL; the equivalent serum MIC, from 298 
the present data, would be of the order of 12.5 µg/mL, which is approximately two to three 299 
times higher than maximum serum concentrations of oxytetracycline achieved in calves with 300 
the recommended dose rate of 20 mg/kg (Nouws and Vree, 1983; Toutain and Raynaud, 301 
1983; Nouws et al., 1990; Brentnall et al., 2013). Alternative mechanisms of action of 302 
oxytetracycline are shown in Appendix C. 303 
 304 
Conclusions 305 
Concentrations of oxytetracycline in serum and broth were not measured at the start 306 
and completion of the in vitro studies; it is possible that reported differences between the 307 
media might have been due, in part, to some degradation of the drug, but at differing rates 308 
over the 24 h incubation periods. Differing bacterial growth rates in the two media are 309 
possible, even likely, and this could contribute to the reported differences. Time-kill studies 310 
were based on fixed concentrations for a pre-defined time period. In vivo, concentrations in 311 
serum and the biophase first increase and then decrease after systemic, non-vascular dosing. 312 
Therefore, in vitro time-kill methods, such as hollow fibre models, better reflect the 313 
circumstances of clinical exposure and could be used in future studies. 314 
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Figure legends 423 
 424 
Fig. 1. Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations 425 
(MBCs) for oxytetracycline against 12 isolates (first six, left to right Mannheimia 426 
haemolytica; second six, left to right Pasteurella multocida) in Mueller Hinton broth (MHB) 427 
and bovine serum. Note the differing ordinate scales. 428 
 429 
Fig. 2. In vitro inhibition of growth of Mannheimia haemolytica over 24 h exposure to five 430 
multiples (0.25 to 4.0) of minimum inhibitory concentration (MIC), measured in either 431 
Mueller Hinton broth (MHB) or serum, for oxytetracycline: (a) MHB and (b) serum (mean for 432 
six isolates in each matrix). Standard error of the mean (SEM) bars not included for clarity. 433 
Dotted line indicates limit of quantification (33 colony forming units, CFU/mL). 434 
 435 
Fig 3. In vitro inhibition of growth of Pasteurella multocida over 24 h exposure to five 436 
minimum inhibitory concentrations (MIC) multiples (0.25 to 4.0) of oxytetracycline, 437 
measured in either Mueller Hinton broth (MHB) or serum: (a) MHB and (b) serum (mean for 438 
six isolates in each matrix). Standard error of the mean (SEM) bars not included for clarity. 439 
Dotted line indicates limit of quantification (33 colony forming units, CFU/mL). 440 
 441 
 442 
 443 
  444 
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Table 1. Oxytetracycline geometric mean standard deviation (SD) minimum inhibitory 445 
concentrations (MICs) and minimum bactericidal concentrations (MBCs) measured in 446 
Mueller Hinton broth (MHB) and serum, along with MIC:MBC and MHB:serum ratios (n = 447 
6). 448 
Matrix MIC 
(µg/mL) 
MBC 
(µg/mL) 
MBC:MIC ratio 
Mannheimia haemolytica 
MHB 
Serum 
Serum:MHB ratio 
0.22 (0.12) 
5.46 (4.61) 
b
 
25.2:1 
2.83 (2.51) 
10.08 (6.20) 
a
 
3.6:1 
13.1:1 
1.9:1 
Pasteurella multocida 
MHB 
Serum 
Serum:MHB ratio 
0.25 (0.08) 
6.75 (2.58)
 b
 
27.4:1 
1.26 (1.33) 
12.67 (4.13)
 b
 
10.1:1 
5.1:1 
1.9:1 
Significant difference between MHB and serum: 
a
 P < 0.05; 
b
 P < 0.01. 449 
 450 
 451 
  452 
Page 18 of 21
 19 
Figure 1. 453 
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Figure 2. 459 
 460 
 461 
 462 
 463 
 464 
  465 
0 4 8 12 16 20 24
10 1
10 2
10 3
10 4
10 5
10 6
10 7
10 8
10 9
10 1 0
0
0.25
0.5
1
2
4
LOD
Oxytetracycline in MHB for M.haemolyticaa
Time (h)
C
F
U
/m
L
0 4 8 12 16 20 24
10 1
10 2
10 3
10 4
10 5
10 6
10 7
10 8
10 9
10 1 0
0
0.25
0.5
1
2
4
LOD
Oxytetracycline in Serum for M.haemolytica
Time (h)
C
F
U
/m
L
b
Page 20 of 21
 21 
Figure 3. 466 
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